Driven by the strong momentum of its two core growth engines—CDMO/CMO clinical development and high-quality exosome raw materials—HeXun Biosciences posted revenue of NT$26.78 million in June. Cumulative revenue for the first half of the year reached NT$151 million, marking a 13.60% year-on-year increase.

In addition to the steady growth of its existing business lines, HeXun recently announced that it has officially submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase I clinical trial of its in-house developed allogeneic mesenchymal stem cell (MSC) therapy, HeXell-2020, for the treatment of frailty syndrome in the elderly.

This submission follows HeXun’s previous success in obtaining U.S. FDA approval to conduct Phase I/IIa clinical trials of HeXell-2020 for the treatment of coronary artery disease (CAD). The company is now further advancing HeXell-2020 technology by expanding its application to other indications within the international clinical trial framework.

In recent years, frailty syndrome has emerged as a critical issue in elderly healthcare and long-term care. According to a 2024 report published in BMJ Global Health, the prevalence of frailty syndrome among the global elderly population ranges from 12% to 24%. Medical and caregiving costs for this group are several times higher than for non-frail individuals, placing a significant financial burden on healthcare systems. HeXell-2020 targets this clearly unmet medical need, offering the potential to improve physical function in elderly patients and opening new application scenarios for HeXun’s cell therapy innovations.

According to market research firm Global Market Insights, the global elderly care services market is projected to grow to US$2.88 trillion by 2032, with a compound annual growth rate (CAGR) of 7.8% from 2024 to 2032.

Looking ahead, HeXun will continue to operate with a dual-track strategy: "R&D drives revenue, and revenue supports R&D" to scale up its operations. On one hand, its current CDMO/CMO clients continue to advance clinical trial projects and the development of high-quality exosome raw materials, sustaining cell production capacity at a stable level. On the other hand, the company is expanding its allogeneic MSC platform, leveraging existing clinical experience in indications such as coronary artery disease and graft-versus-host disease, and steadily progressing its pipeline to include new drug development for neurodegeneration, immune modulation, and tissue regeneration. In the future, HeXun will accelerate the integration of its cell manufacturing capabilities with clinical translation resources, further expanding its CDMO and licensing partnership business model.

Resource: 和迅上半年營收1.51億元 年增13.60％